Pacifico Biolabs develops protein ingredients using mycelium fermentation technology and produces them in standard beer brewery fermentation tanks rather than purpose-built bioreactors. By repurposing existing brewery infrastructure the company seeks to lower production costs and scale more quickly using underutilised fermentation capacity. Pacifico positions its product as a domestically produced protein alternative to imported feed protein, aiming to shorten supply chains and reduce environmental and geopolitical exposure. The company plans to scale production in Saxony, Germany, expand its team, and roll out commercial launches across the DACH region and Nordic Europe, targeting retail launches by late 2026. The recent €7 million Series A will fund those near-term expansion and commercialization efforts.

Total raised

$11M

Funding rounds

2

Latest round

Series A

Latest activity

May 2026